This Week in Surgery — Jun 18, 2026

Welcome to This Week in Surgery. This week we're covering 9 notable papers spanning the integration of artificial intelligence into clinical practice, key refinements in oncologic surgery, and a look at long-term trial data and the future of surgical training. Let's dive in.

First up, we explore the expanding role of artificial intelligence, with three papers showcasing its potential from high-level decision making to diagnostics and drug discovery. A report in Nature introduces MIRA, an autonomous AI agent designed to operate within a sandboxed electronic health record [1]. In simulations of real patient cases, this agent could manage the entire clinical workflow—from taking histories and ordering tests to formulating treatment plans, including prescribing medications and scheduling surgery. Notably, MIRA was found to outperform physicians in diagnostic accuracy and made guideline-concordant decisions. While this is an early proof-of-concept needing extensive real-world validation, it suggests a future where AI partners can translate clinical intent into structured, actionable EHR operations. Moving from autonomous agents to assistive tools, a study in Surgical Endoscopy presents an AI system to improve the diagnosis of pancreatic diseases on endoscopic ultrasound [3]. This multi-module system first classifies image types and filters out low-quality images, then provides a multi-label classification for six different pancreatic diseases. The key finding was its impact on training: when novice endoscopists used the AI for assistance, their diagnostic performance significantly improved, with one novice's accuracy jumping from under 40 percent to over 57 percent. Finally, demonstrating AI's reach into therapeutics, a paper in Science Translational Medicine describes using deep learning to discover new antibiotics effective against Neisseria gonorrhoeae [7]. By training a model on a large screen of small molecules, researchers were able to virtually screen about 6 million compounds. This led to the identification of 83 active inhibitors, including two structurally novel compounds that were rapidly bactericidal against multidrug-resistant strains and showed promise in preclinical models. This highlights how AI can accelerate the discovery pipeline for urgently needed antimicrobials.

Our next theme is the refinement of cancer surgery, focusing on de-escalation and precision. The QuickSilver study, published in Annals of Surgical Oncology, challenges the routine use of neoadjuvant therapy in rectal cancer [2]. The phase II trial enrolled patients with Stage II or III rectal cancer who were deemed 'margin-clear' on preoperative MRI. These patients proceeded directly to surgery. At two years, the oncologic outcomes for the 80 patients with final pathology of Stage II or III were excellent: the local recurrence rate was just 1 percent, and disease-free survival was 85 percent. Importantly, only 8 percent of these patients ended up needing adjuvant radiotherapy, suggesting that for a carefully selected group, neoadjuvant treatment can be safely omitted. In breast cancer, a trial in JAMA Surgery addresses the persistent problem of positive margins during breast-conserving surgery [9]. Investigators evaluated an intraoperative specimen PET-CT imaging technique. Patients received a low dose of FDG before surgery, and the excised specimen was imaged in the operating room. If the PET-CT scan suggested a close or positive margin, the surgeon excised additional tissue immediately. This intervention was highly effective, increasing the success rate of achieving negative margins for the invasive component from 76 percent without any intraoperative assessment to nearly 92 percent with specimen PET-CT. This approach could substantially reduce the need for re-operations. And delving into the molecular underpinnings of cancer, a study in Science Translational Medicine investigated why some EGFR-mutant lung adenocarcinomas transform into squamous cell carcinomas, a key mechanism of resistance to targeted therapy [6]. Through comprehensive multiomic profiling, the researchers identified that inactivation of the retinoblastoma, or Rb, pathway is a hallmark of this transformation. They also found that this process up-regulates the MET pathway, identifying MET signaling as a potential therapeutic vulnerability. In patient-derived xenograft models, combining EGFR and MET inhibition suppressed tumor growth, suggesting a new strategy to overcome this form of treatment resistance.

Finally, we turn to landmark trial data and future directions for the specialty. A major publication in The Lancet reports the 20-year results of a large, multicenter randomized trial on patellar resurfacing during total knee replacement [4]. The primary outcome, the Oxford Knee Score, showed no significant difference between the resurfacing and no-resurfacing groups over the 20-year follow-up. However, a closer look reveals that while not statistically significant, most clinical outcomes, including complications and reoperations, trended in favor of resurfacing. More importantly, the resurfacing group accrued significantly more quality-adjusted life-years, or QALYs, at no significant difference in overall healthcare costs. The authors conclude that patellar resurfacing has a 99 percent probability of being cost-effective, weighting the evidence towards it being the approach of first choice. In transplantation, a phase 1/2a trial in Science Translational Medicine presents a novel strategy to induce tolerance without harsh conditioning [8]. In living-donor kidney transplant recipients, a combination of donor bone marrow cells and recipient regulatory T cells was administered post-transplant. This cell therapy successfully induced donor leukocyte chimerism across multiple lineages, a primary endpoint that was not met in any control patient. This immunomodulation allowed for immunosuppression to be minimized to belatacept monotherapy in three patients and appeared to dampen the anti-donor T cell response. This is a crucial proof-of-concept for achieving chimerism-based tolerance without the need for toxic recipient irradiation. Lastly, a viewpoint in the Journal of the American College of Surgeons addresses a major shift in surgical practice: the collapse in bariatric surgery volume due to the widespread use of GLP-1 receptor agonists [10]. The authors argue this 'demand shock' exposes fundamental problems in MIS fellowship training. They call for three major reforms: first, moving core MIS and robotic credentialing into residency training under enforceable standards; second, consolidating high-volume bariatric centers; and third, contracting the number of fellowships while recalibrating their curricula to train multifaceted MIS surgeons rather than bariatric-only specialists. This piece raises critical questions about how surgical training must adapt to rapid changes in medical therapy.

If you only have time for one paper this week, make it the 20-year follow-up of patellar resurfacing in total knee replacement, from The Lancet [4]. This study provides the long-term, high-quality evidence needed to guide a very common surgical decision, concluding that while clinical scores are similar, resurfacing is the more cost-effective strategy over the long run.

Here are the key takeaways from this week in Surgery: First, for patients undergoing total knee replacement, routine patellar resurfacing is likely the most cost-effective approach, providing more quality-adjusted life-years over two decades at no additional overall cost [4]. Second, in carefully selected patients with margin-clear Stage II or III rectal cancer on MRI, a direct-to-surgery strategy offers excellent two-year oncologic outcomes while avoiding the morbidity of neoadjuvant radiation [2]. Third, intraoperative specimen PET-CT is a promising technique in breast-conserving surgery, significantly improving the rate of achieving negative margins and potentially reducing re-excision rates [9]. Fourth, a new cell therapy combining donor bone marrow and recipient regulatory T-cells has shown it can induce immune tolerance in kidney transplant recipients without the need for toxic irradiation, a major step forward for the field [8]. Finally, the sharp decline in bariatric surgery volume due to GLP-1 agonists is prompting calls to restructure MIS fellowship training, with an emphasis on moving core robotic skills into residency [10].

That's your roundup for This Week in Surgery. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.